Napo Pharmaceuticals, a subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX), has submitted an Investigational New Drug (IND) application to the FDA for a new formulation of crofelemer powder for oral solution for the treatment of microvillus inclusion disease (MVID). The disease is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children. Crofelemer has been granted Orphan Drug Designation (ODD) by the FDA and the European Medicines Agency (EMA) for MVID and short bowel syndrome (SBS).